Taysha Gene Therapies, Inc. Proceeds from (Payments for) Other Financing Activities
Taysha Gene Therapies, Inc. (TSHA) reported Proceeds from (Payments for) Other Financing Activities of $94.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromPaymentsForOtherFinancingActivities · last filed 2026-08-11
- Taysha Gene Therapies, Inc. proceeds from (payments for) other financing activities for the quarter ending 2026-06-30 was $75.00K, a 36.44% decline year-over-year.
- Taysha Gene Therapies, Inc. proceeds from (payments for) other financing activities for the quarter ending 2026-03-31 was $19.00K.
- Taysha Gene Therapies, Inc. proceeds from (payments for) other financing activities for the quarter ending 2025-12-31 was -$90.00K, a 309.30% decline year-over-year.
- Taysha Gene Therapies, Inc. proceeds from (payments for) other financing activities for the quarter ending 2025-09-30 was -$285.00K.
- Taysha Gene Therapies, Inc. proceeds from (payments for) other financing activities for fiscal 2025 was -$337.00K.
- Taysha Gene Therapies, Inc. proceeds from (payments for) other financing activities for fiscal 2024 was -$167.00K.
- Taysha Gene Therapies, Inc. proceeds from (payments for) other financing activities for fiscal 2023 was -$229.00K.
- Taysha Gene Therapies, Inc. proceeds from (payments for) other financing activities for fiscal 2022 was -$1.04M.
| Period end | Proceeds from (Payments for) Other Financing Activities 3 month | Proceeds from (Payments for) Other Financing Activities 3 month as first filed | Proceeds from (Payments for) Other Financing Activities 6 month | Proceeds from (Payments for) Other Financing Activities 6 month as first filed | Proceeds from (Payments for) Other Financing Activities 9 month | Proceeds from (Payments for) Other Financing Activities 9 month as first filed | Proceeds from (Payments for) Other Financing Activities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $75.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $94.00K 10-Q · filed 2026-08-11 | $4.00K derived: sum of 3 quarters · filed 2026-08-11 | -$281.00K derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | $19.00K 10-Q · filed 2026-05-06 | -$71.00K derived: sum of 2 quarters · filed 2026-05-06 | -$356.00K derived: sum of 3 quarters · filed 2026-05-06 | -$238.00K derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | -$90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$375.00K derived: sum of 2 quarters · filed 2026-03-19 | -$257.00K derived: sum of 3 quarters · filed 2026-08-11 | -$337.00K 10-K · filed 2026-03-19 | |||
| 2025-09-30 | -$285.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$167.00K derived: sum of 2 quarters · filed 2026-08-11 | -$247.00K 10-Q · filed 2025-11-04 | -$204.00K derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $118.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $38.00K 10-Q · filed 2026-08-11 | $81.00K derived: sum of 3 quarters · filed 2026-08-11 | -$86.00K derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | -$80.00K 10-Q · filed 2026-05-06 | -$37.00K derived: sum of 2 quarters · filed 2026-05-06 | -$204.00K derived: sum of 3 quarters · filed 2026-05-06 | -$217.00K derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$124.00K derived: sum of 2 quarters · filed 2026-03-19 | -$137.00K derived: sum of 3 quarters · filed 2026-03-19 | -$167.00K 10-K · filed 2026-03-19 | |||
| 2024-09-30 | -$167.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$180.00K derived: sum of 2 quarters · filed 2025-11-04 | -$210.00K 10-Q · filed 2025-11-04 | -$170.00K 10-Q · filed 2024-11-13 | -$186.00K derived: sum of 4 quarters · filed 2025-11-04 | ||
| 2024-06-30 | -$13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$43.00K 10-Q · filed 2025-08-12 | -$19.00K derived: sum of 3 quarters · filed 2025-08-12 | -$116.00K derived: sum of 4 quarters · filed 2025-08-12 | |||
| 2024-03-31 | -$30.00K 10-Q · filed 2025-05-15 | -$6.00K derived: sum of 2 quarters · filed 2025-05-15 | -$103.00K derived: sum of 3 quarters · filed 2025-05-15 | -$226.00K derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$73.00K derived: sum of 2 quarters · filed 2025-02-26 | -$196.00K derived: sum of 3 quarters · filed 2025-02-26 | -$229.00K 10-K · filed 2025-02-26 | |||
| 2023-09-30 | -$97.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$220.00K derived: sum of 2 quarters · filed 2024-11-13 | -$253.00K 10-Q · filed 2024-11-13 | -$586.00K derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | -$123.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$156.00K 10-Q · filed 2024-08-12 | -$489.00K derived: sum of 3 quarters · filed 2024-08-12 | -$432.00K derived: sum of 4 quarters · filed 2024-08-12 | |||
| 2023-03-31 | -$33.00K 10-Q · filed 2024-05-14 | -$366.00K derived: sum of 2 quarters · filed 2024-05-14 | -$309.00K derived: sum of 3 quarters · filed 2024-05-14 | -$842.00K derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | -$333.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$276.00K derived: sum of 2 quarters · filed 2024-03-19 | -$809.00K derived: sum of 3 quarters · filed 2024-03-19 | -$1.04M 10-K · filed 2024-03-19 | |||
| 2022-09-30 | $57.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$476.00K derived: sum of 2 quarters · filed 2023-11-14 | -$709.00K 10-Q · filed 2023-11-14 | -$1.14M 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | -$533.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$766.00K 10-Q · filed 2023-08-14 | -$1.05M 10-Q · filed 2022-08-11 | ||||
| 2022-03-31 | -$233.00K 10-Q · filed 2023-05-11 | -$368.00K 10-Q · filed 2022-05-16 | |||||
| 2021-12-31 | -$514.00K 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |